Physician profile
David A Kasper
NPI 1811175649
$333,009.40
in general payments reported to CMS, 2019-2025
41 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $13K · 2021: $42K · 2022: $61K · 2023: $91K · 2024: $55K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Consulting Fee: $22K · Food and Beverage: $15K · Travel and Lodging: $12K · Honoraria: $2,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,731.50 |
| Consulting Fee | $22,200.00 |
| Food and Beverage | $14,715.34 |
| Travel and Lodging | $11,648.17 |
| Honoraria | $2,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $120,016.67 | 2019-2024 | Otezla |
| Abbvie INC. | $54,038.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $36,815.53 | 2021-2025 | Sotyktu |
| Pfizer INC. | $36,539.36 | 2019-2025 | |
| Dermavant Sciences, INC. | $32,019.75 | 2022-2024 | Vtama |
| Celgene Corporation | $24,523.03 | 2019 | |
| Sun Pharmaceutical Industries INC. | $5,022.84 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $4,467.97 | 2019-2025 | Dupixent, Libtayo |
| Verrica Pharmaceuticals INC. | $4,197.89 | 2023-2024 | Ycanth |
| Janssen Biotech, INC. | $3,861.51 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Lnhc, INC | $2,884.26 | 2025 | Zelsuvmi |
| Galderma Laboratories, L.P. | $1,814.82 | 2019-2025 | Epsolay, Nemluvio, Aklief |
| Leo Pharma INC. | $793.89 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $741.59 | 2019-2025 | |
| Genzyme Corporation | $711.36 | 2019-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.